Innovative and accredited continuing medical education
for today’s practicing clinicians.

CME Institute is trusted by physicians across medical specialties for premium continuing education that yields the highest educational outcomes. These ACCME-accredited activities make the latest research, novel therapies, and clinical best practices accessible and approachable for physician, NP, PA, and PharmD learners.

Expert-led insights to improve patient outcomes
Multi-modal courses to suit all learning styles
Timely topics for relevant application to practice
Razor-focused approach to innovation that includes documentary-style video and micro-learning Tweetorials
A commitment to collective mindfulness

Recent courses

Journal Treatment-Resistant Mood Disorders in LGBTQ People: A Retrospective Study of Clinical Features and Response to Electroconvulsive Therapy Mood Disorders Depression Electroconvulsive Therapy In this chart review, LGBTQ people with treatment-resistant mood disorders had clinical features linked to worse outcomes, but their improvement with ECT was similar to that seen in non-LGBTQ patients. 1.00 AMA PRA Category 1 Credit™ 1.00 Participation	Journal The Co-occurrence of Gastrointestinal Symptoms and Psychosis: Diagnostic Considerations Psychotic Disorders Gastroenterology There are numerous clinical scenarios in which gastrointestinal and psychotic symptoms commonly co-occur; thus, it is important that both psychiatrists and primary care physicians have a familiarity with the differential diagnosis. 1.00 AMA PRA Category 1 Credit™ 1.00 Participation	Journal Suicide Risk in a National VA Sample: Roles of Psychiatric Diagnosis, Behavior Regulation, Substance Use, and Smoking Bipolar Disorder Schizophrenia/ Schizoaffective Disorders Smoking Substance Use Disorders Suicide Veterans and Military Issues Predicting suicide is difficult, as suicidal behavior is not linked solely to any single behavior or psychiatric diagnosis. This study compared risk of suicidal behavior among a transdiagnostic sample of Veterans with varying disorders and behaviors. 1.00 AMA PRA Category 1 Credit™ 1.00 Participation
Self-study / Enduring Tweetorial: Diagnosing and Treating Alzheimer Disease During the Early Stage Alzheimer Disease Dementia Integrated Care Neuroimaging Patient/Physician Communication Primary Care Prompt treatment of early-stage Alzheimer disease (AD) can curb symptom progression. Tests for biomarkers, new symptomatic treatments and disease-modifying agents, and the addition of the preclinical stage to AD diagnostic criteria can aid in earlier disease recognition and building treatment plans. 0.25 AMA PRA Category 1 Credit™ 0.25 Participation	Video Facilitating Treatment Initiation in Early-Stage Alzheimer Disease Alzheimer Disease Dementia Integrated Care Neuroimaging Patient/Physician Communication Primary Care Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field. 0.50 AMA PRA Category 1 Credit™ 0.50 Participation	Video Timely Diagnosis of Alzheimer Disease Alzheimer Disease Dementia Neuroimaging Primary Care Early-stage diagnosis of Alzheimer disease leads to prompt treatment initiation and better patient QoL. Learn about new guidelines and technology advances and what’s on the horizon from authorities in the field. 0.50 AMA PRA Category 1 Credit™ 0.50 Participation
Journal Long COVID in Children and Adolescents Child and Adolescent Psychiatry Long COVID symptoms are both physical and mental in nature among children and adolescents and have the potential to affect long-term functioning and increase the overall burden on health care delivery. 1.00 AMA PRA Category 1 Credit™ 1.00 Participation	Webinar recorded A Review of Disease Mechanisms and Current and Emerging Treatment Options for Generalized Myasthenia Gravis Myasthenia Gravis Patients with generalized myasthenia gravis (gMG) receive multiple immunosuppressive therapies, but with incomplete suppression of IgG autoantibodies. Review this update on gMG to learn about novel therapies that can more effectively suppress IgG autoantibodies through a novel mechanism of action to help your patients achieve better clinical outcomes. 1.00 AMA PRA Category 1 Credit™ 1.00 Participation	Self-study / Enduring Tweetorial: Myasthenia Gravis Disease Mechanisms and the Changing Treatment Landscape Myasthenia Gravis Patients with generalized myasthenia gravis (gMG) receive multiple immunosuppressive therapies, but with incomplete suppression of IgG autoantibodies. Read this rapid update in gMG to learn about novel therapies that can more effectively suppress IgG autoantibodies through a novel mechanism of action to help your patients achieve better clinical outcomes. 0.25 AMA PRA Category 1 Credit™ 0.25 Participation

Pages

My Courses

Please login or create an account to view your activities.

Transcript

Please login or create an account to view your activities.